Exfoliation syndrome (XFS) is an age-related, generalized disorder of the extracellular matrix characterized by progressive accumulation of abnormal fibrillar material in intra- and extra-ocular tissues.
It is estimated to affect around 80 million people worldwide, and 10–20% of people aged >60 years are severely affected by XFS. This disorder is also associated with a progressive form of chronic open-angle glaucoma and is the second most common cause of irreversible blindness globally.
XFG is characterized by deposition of exfoliation material in the anterior segment of the eyes, obstructing aqueous humor outflow, resulting in elevated intraocular pressure and secondary open-angle glaucoma.
Relative to primary open-angle glaucoma, XFS-associated secondary open-angle glaucoma is associated with a more severe prognosis, higher elevated intraocular pressure, and more severe optic nerve lesions at the time of diagnosis.
A team of researchers has identified a genetic mutation associated with exfoliation syndrome, characterized by abnormal protein material accumulating in the front of the eye.
It is the most common cause of glaucoma and a major cause of irreversible blindness. The findings could lead to further research on the causes of the systemic disorder and potential cures.
A team of researchers from the Agency for Science, Technology and Research’s (A*STAR) Genome Institute of Singapore (GIS) and Bioprocessing Technology Institute (BTI), as well as Singapore Eye Research Institute (SERI), have identified a genetic mutation (functionally defective CYP39A1 gene) associated with exfoliation syndrome, the most common cause of glaucoma.
The findings could pave the way for future research on the cause of exfoliation syndrome and potential cures. Their research was published in the Journal of the American Medical Association (JAMA) on 24 February 2021.
Exfoliation syndrome is a systemic disorder characterized by abnormal protein material that progressively accumulates in the front of the eye. This disorder is the most common cause of glaucoma and a major cause of irreversible blindness.
In this study, the scientists sequenced all protein-encoding genes of more than 20,000 participants from 14 countries across Asia, Europe, and Africa, including more than 1,200 Singaporeans.
They observed that people with exfoliation syndrome are twice as likely to carry damaging mutations in the gene encoding for the CYP39A1 protein, an enzyme that plays an important role in the processing of cholesterol.
Further extended analyses suggest that defective CYP39A1 function is strongly associated with increased risk of exfoliation syndrome.
Although exfoliation syndrome is the most common cause of glaucoma, its origin is shrouded in mystery because it is not known where the abnormal protein deposits (exfoliative material) originate, and how the disease comes about.
Answers to these questions could provide approaches to design and develop an effective treatment. The current findings point to the important role of cholesterol processing in the exfoliation syndrome disease process.
As cholesterol is found abundantly in all cells, disruption to how cholesterol is processed due to defective CYP39A1 activity could adversely impact their normal functions.
In particular, this study discovered that epithelial cells in the front of the eye responsible for filtering the blood supply to produce the clear fluid known as aqueous humor that bathes and nourishes other cells in the eye were most affected by the CYP39A1 gene mutation.
Disruption to the gene function can compromise the filtering function of epithelial cells and lead to leakage of exfoliative material from the blood into the eye.
Prof Patrick Tan, Executive Director of GIS, said, “This is a ground-breaking study that could facilitate future research efforts aimed at restoring defective CYP39A1 function and inhibiting the formation of exfoliation material in the eye as treatments for exfoliation syndrome and glaucoma.”
Prof Aung Tin, Director of SERI and Deputy Medical Director of SNEC, said, “This is a major eye disease, affecting over 70 million people worldwide, which causes a lot of visual morbidity and blindness, not only from glaucoma but also due to complications related to cataract surgery.
“This study was notable for involving many centers from many different countries around the world but led from Singapore. The study findings are very exciting as we found a new pathway for the disease which opens up possibilities for new treatments.”
Prof David Friedman, the Albert and Diane Kaneb Chair in Ophthalmology at Harvard University and Director of the Glaucoma Service at the Massachusetts Eye and Ear Infirmary, Boston, commented, “Very exciting work. The researchers have identified rare gene variants that result in disrupted cholesterol homeostasis and transport that will open the door to novel therapeutics.
“Having studied over 20,000 individuals, the study demonstrates the power of studying rare variants to detect disease-causing genes in complex conditions.” Prof Friedman was not involved in the study.
The post The Gene Mutation – Exfoliation Syndrome & Glaucoma appeared first on Ophthalmology Breaking News.
more recommended stories
Ardena’s Expertise Helps New Treatment for Parkinson’s Disease
Ghent, Belgium 30 August 2021: Ardena,.
The Fight for Air Climb and Other Extraordinary Feats by People With PF
A couple of weeks ago, Bert.
Inflatable Neurostimulator for Minimally Invasive Pain Control
Researchers at the University of Cambridge.
Glucagon-like Peptide-1 Metabolism is Impacted by Anthocyanins and (-)-epicatechin
Obesity and diabetes are major health.
The Last Mile: Overcoming COVID-19 Vaccine Hesitancy
Special thanks to Marc Benjamin, a.
The latest science on staying healthy during pregnancy
New research examines prenatal supplements, how.
Relapsed, Refractory Follicular Lymphoma: CAR-T Cell Therapy Shows Promise
Axicabtagene ciloleucel (axi-cel) appears to be.
Living With PTSD? How to Manage Anxiety and Flashbacks
If you have post-traumatic stress disorder (PTSD), you.
Strategic Partnership Announced Between IDBS and Scitara
Biopharmaceutical lifecycle management platform IDBS (Guildford,.
DLBCL: Naratuximab Shows Promise Among Patients With Relapsed/Refractory Disease
Among patients with diffuse large B.